Clinical Trials Logo

Varicella clinical trials

View clinical trials related to Varicella.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05460429 Recruiting - Varicella Clinical Trials

Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus

Start date: July 30, 2022
Phase: Phase 4
Study type: Interventional

This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity and safety of a single dose of varicella vaccine in healthy children aged 1-6 years with different varicella immunization histories, to evaluate the antibody level of varicella-zoster virus in healthy people aged 0-59 years in Zhejiang Province.

NCT ID: NCT05422508 Recruiting - Varicella Clinical Trials

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Start date: July 5, 2022
Phase: Phase 2
Study type: Interventional

- Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination - Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination

NCT ID: NCT04471493 Recruiting - Influenza Clinical Trials

Pediatric and Ambulatory Research in Infectious Diseases

PARI
Start date: June 26, 2017
Phase:
Study type: Observational [Patient Registry]

Many ambulatory networks are mainly based on diagnoses made by first-line physicians not specifically trained to join the network. Here we aim to set up a surveillance network on pediatric infectious diseases with an investment in teaching with specific trainings of participating pediatricians, increasing in use of point of care tests, and automated data extraction from the computers of the pediatricians.

NCT ID: NCT01866566 Recruiting - Varicella Clinical Trials

The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination

Start date: June 2013
Phase: Phase 4
Study type: Interventional

Through evaluating the immunogenicity and safety for Varicella vaccine two doses immune procedure we could supply scientific and practical evidence for this two doses immune procedure promotion and management.

NCT ID: NCT00492739 Recruiting - Immunosuppression Clinical Trials

Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients

VZVinOLTx
Start date: June 2007
Phase: Phase 2/Phase 3
Study type: Interventional

Varicella is a vaccine-preventable disease, which can be severe in immunosuppressed children. Currently, the (live) vaccine is not recommended in pediatric orthotopic liver transplant recipients. Furthermore, protection due to naturally acquired immunity to VZV or post-immunization isn't well described in this population.The questions asked are: - What is the influence of the immunosuppression required after orthotopic liver transplantation (OLT) on the maintenance of VZV-specific immunity elicited by wild-type varicella infection before OLT transplantation? - What is the influence of the immunosuppression required after OLT on VZV-specific immunity elicited by varicella immunization before OLT transplantation? - What is the influence of the residual immunosuppression at ≥ 12 months after OLT transplantation on the induction of VZV-specific B and T cell responses elicited by VZV vaccination after OLT transplantation? - What is the influence of the residual immunosuppression at ≥ 12 months after OLT transplantation on the persistence / waning of B and T cell responses elicited by VZV vaccination?